The proteolytic systems of muscle wasting

Recent Advances in DNA and Gene Sequences

Volumn 9, Issue 1, 2015, Pages 26-35

  Scicchitano, Bianca Maria ^a   Faraldi, Martina ^b   Musarò, Antonio ^b,c  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

Autophagy; Calpain; Caspases; Muscle atrophy; Muscle wasting; Ubiquitin proteasome system

Indexed keywords

CALPAIN; CASPASE; PROTEASOME; UBIQUITIN;

ARTICLE; AUTOPHAGY; CATABOLISM; HUMAN; MOLECULAR PATHOLOGY; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REGULATORY MECHANISM; SKELETAL MUSCLE; CACHEXIA; GENETICS; METABOLISM; MUSCLE FIBRIL; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

CACHEXIA; HUMANS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; MYOFIBRILS; PROTEOLYSIS; SIGNAL TRANSDUCTION;

EID: 85011556481     PISSN: 23520922     EISSN: 23520930     Source Type: Journal    
DOI: 10.2174/2352092209999150911121502     Document Type: Article

References (139)

1. Tajbakhsh S, Cossu G. Establishing myogenic identity during somitogenesis. Curr. Opin. Genet Dev 1997; 7: 634-41.
2. Arnold HH, Braun T. Targeted inactivation of myogenic factor genes reveals their role during mouse myogenesis: a review. Int J Dev Biol 1996; 40: 345-53.
3. Bendall AJ, Ding J, Hu G, et al. Msx1 antagonizes the myogenic activity of Pax3 in migrating limb muscle precursors. Development 1999; 126: 4965-76.
4. Brohmann H, Jagla K, Birchmeier C. The role of Lbx1 in migration of muscle precursor cells. Development 2000; 127: 437-45.
5. Gross MK, Moran-Rivard L, Velasquez T, et al. Lbx1 is required for muscle precursor migration along a lateral pathway into the limb. Development 2000; 127: 413-424.
6. Wang Y, Sassoon D. Ectoderm-mesenchyme and mesenchymemesenchyme interactions regulate Msx-1 expression and cellular differentiation in the murine limb bud. Dev Biol 1995; 168: 374-82.
7. Yang XM, Vogan K, Gros P, et al. Expression of the met receptor tyrosine kinase in muscle progenitor cells in somites and limbs is absent in Splotch mice. Development 1996; 122: 2163-71.
8. Tajbakhsh S, Rocancourt D, Cossu G, et al. Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. Cell 1997; 89: 127-138.
9. Hughes SM, Taylor JM, Tapscott SJ, et al. Selective accumulation of MyoD and myogenin mRNAs in fast and slow adult skeletal muscle is controlled by innervation and hormones. Development 1993; 118: 1137-47.
10. McKinsey TA, Zhang CL, Olson EN. Control of muscle development by dueling HATs and HDACs. Curr Opin Genet Dev 2001; 11: 497-504.
11. Musaro A, Cusella De Angelis MG, Germani A, et al. Enhanced expression of myogenic regulatory genes in aging skeletal muscle. Exp Cell Res 1995; 8: 221-41.
12. Dedkov EI, Kostrominova TY, Borisov AB, et al. MyoD and myogenin protein expression in skeletal muscles of senile rats. Cell Tissue Res 2003; 15: 311-401.
13. Musaro A. The basis of muscle regeneration. Adv Biol 2014; 2014: 1-16.
14. Berthier C, Blaineau S. Supramolecular organization of the subsarcolemmal cytoskeleton of adult skeletal muscle fibers. A review. Biol Cell 1997; 89: 413-34.
15. Durbeej M, Campbell KP. Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Curr Opin Genet Dev 2002; 12: 349-61.
16. Smart EJ, Graf GA, McNiven MA, et al. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 1999; 19: 7289-304.
17. Song KS, Scherer PE, Tang Z, et al. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem. 1996; 271: 15160-65.
18. Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 1998; 18: 365-368.
19. Bonaldo P, Sandri M. Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech 2013; 6: 25-39.
20. Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov 2015; 14: 58-74.
21. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev 2000; 1: 11-21.
22. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium–apoptosis link. Nat Rev 2003; 4: 552-565.
23. Gillis JM. Membrane abnormalities and Ca homeostasis in muscles of the mdx mouse, an animal model of the Duchenne muscular dystrophy: a review. Acta Physiol Scand 1996; 156: 397-406.
24. Barbieri E, Sestili P. Reactive Oxygen Species in SkeletalMuscle Signaling. J Sig Trans 2012; 2012: 1-17.
25. Joyce PI, Satija R, Chen M, et al. The atypical calpains: evolutionary analyses and roles in Caenorhabditis elegans cellular degeneration. PLoS Genet 2012; 8: e1002602.
26. Sorimachi H, Ishiura S, Suzuki K. Structure and physiological function of calpains. Biochem J 1997; 328: 721-32.
27. Sorimachi H, Imajoh-Ohmi S, Emori Y, et al. Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and mu-types. Specific expression of the mRNA in skeletal muscle. J Biol Chem 1989; 264: 20106-111.
28. Ermolova N, Kramerova I, Spencer MJ. Autolytic activation of calpain 3 proteinase is facilitated by calmodulin protein. J Biol Chem 2015; 290: 996-1004.
29. Lebart MC, Benyamin Y. Calpain involvement in the remodeling of cytoskeletal anchorage complexes. FEBS J 2006; 273: 3415-26.
30. Franco SJ, Huttenlocher A. Regulating cell migration: calpains make the cut. J Cell Sci 2005; 118: 3829-38.
31. Goll DE, Neti G, Mares SW, et al. Myofibrillar protein turnover: the proteasome and the calpains. J Anim Sci 2008; 86: E19–35.
32. Evans JS, Turner MD. Emerging functions of the calpain superfamily of cysteine proteases in neuroendocrine secretory pathways. J Neurochem 2007; 103: 849–59.
33. Janossy J, Ubezio P, Apati A, et al. Calpain as a multi-site regulator of cell cycle. Biochem Pharmacol 2004; 67: 1513-21.
34. Storr SJ, Carragher NO, Frame MC, et al. The calpain system and cancer. Nat Rev Cancer 11: 364–74.
35. Johnson JD, Han Z, Otani K, et al. RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets. J Biol Chem 2004; 279: 794-802.
36. Tomimatsu Y, Idemoto S, Moriguchi S, et al. Proteases involved in long-term potentiation. Life Sci 2002; 72: 355-61.
37. Belcastro AN, Shewchuk LD, Raj DA. Exercise-induced muscle injury: a calpain hypothesis. Mol Cell Biochem. 1998; 179: 135-145.
38. Armstrong RB, Warren GL, Warren JA. Mechanisms of exerciseinduced muscle fibre injury. Sports Med 1991; 12: 184-207.
39. Friden J, Sfakianos PN, Hargens AR. Blood indices of muscle injury associated with eccentric muscle contractions. J Orthop Res 1989; 7: 142-5.
40. Cannon JG, Meydani SN, Fielding RA, et al. Acute phase response in exercise. II. Associations between vitamin E, cytokines, and muscle proteolysis. Am J Physiol 1991; 260: R1235-40.
41. Kumamoto T, Kleese WC, Cong JY, et al. Localization of the Ca(2+)-dependent proteinases and their inhibitor in normal, fasted, and denervated rat skeletal muscle. Anat Rec 1992; 232: 60-77.
42. Huang J, Forsberg NE. Role of calpain in skeletal-muscle protein degradation. Proc Natl Acad Sci USA 1998; 95: 12100-05.
43. Martin SJ, O'Brien GA, Nishioka WK, et al. Proteolysis of fodrin (non-erythroid spectrin) during apoptosis. J Biol Chem 1995; 270: 6425-8.
44. Planey SL, Litwack G. Glucocorticoid-induced apoptosis in lymphocytes. Biochem. Biophys. Res Commun 2000; 279: 307-12.
45. Goll DE, Thompson VF, Li H, et al. The calpain system. Physiol Rev 2003; 83: 731-801
46. Saido TC, Sorimachi H, Suzuki K. Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J. 1994; 8: 814-22.
47. Di Lisa F, De Tullio R, Salamino F, et al. Specific degradation of troponin T and I by mu-calpain and its modulation by substrate phosphorylation. Biochem J 1995; 308: 57-61.
48. Kunimatsu M, Ma XJ, Ozaki Y, et al. Neutrophil chemotactic Nacetyl peptides from the calpain small subunit are also chemotactic for immunocytes. Biochem. Mol Biol Int 1995; 35: 247-54.
49. Spencer MJ, Croall DE, Tidball JG. Calpains are activated in necrotic fibers from mdx dystrophic mice. J Biol Chem 1995; 270: 10909-1094.
50. Baghdiguian S, Martin M, Richard I, et al. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat Med 1999; 5: 503-11.
51. Spencer MJ, Guyon JR, Sorimachi H, et al. Stable expression of calpain 3 from a muscle transgene in vivo: immature muscle in transgenic mice suggests a role for calpain 3 in muscle maturation. Proc. Natl Acad Sci USA 2002; 99: 8874-79.
52. Gokhin DS, Tierney MT, Sui Z, et al. Calpain-mediated proteolysis of tropomodulin isoforms leads to thin filament elongation in dystrophic skeletal muscle. Mol Biol Cell 2014; 25: 852-65.
53. Chaudhary P, Suryakumar G, Prasad R, Singh SN, Ali S, Ilavazhagan G. Chronic hypobaric hypoxia mediated skeletal muscle atrophy: role of ubiquitin-proteasome pathway and calpains. Mol Cell Biochem 2012; 364: 101-13.
54. Samengo G, Avik A, Fedor B, et al. Age-related loss of nitric oxide synthase in skeletal muscle causes reductions in calpain Snitrosylation that increase myofibril degradation and sarcopenia. Aging Cell 2012; 11: 1036-45.
55. Barja G. Free radicals and aging. Trends Neurosci 2004; 27: 595-600.
56. Musaro A, Fulle S, Fano G. Oxidative stress and muscle homeostasis. Curr Opin Clin Nutr Metab Care 2010; 13: 236-42.
57. Smuder AJ, Kavazis AN, Hudson MB, et al. Oxidation enhances myofibrillar protein degradation via calpain and caspase-3. Free Radic Biol Med 2010; 49: 1152-60.
58. McClung JM, Judge AR, Talbert EE, et al. Calpain-1 is required for hydrogen peroxide-induced myotube atrophy. Am J Physiol Cell Physiol 2009; 296: C363-71.
59. Tidball JG, Spencer MJ. Expression of a calpastatin transgene slows muscle wasting and obviates changes in myosin isoform expression during murine muscle disuse. J Physiol 2002; 545: 819-28.
60. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996; 335: 1897-1905.
61. Mitch WE, Bailey JL, Wang X, et al. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am J Physiol 1999; 276: C1132-38.
62. Mitch WE, Price SR. Mechanisms activating proteolysis to cause muscle atrophy in catabolic conditions. J Ren Nutr 2003; 13: 149-52.
63. Zamir O, Hasselgren PO, Kunkel SL, et al. Evidence that tumor necrosis factor participates in the regulation of muscle proteolysis during sepsis. Arch Surg 1992; 127: 170-4.
64. Jagoe RT, Goldberg AL. What do we really know about the ubiquitin- proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 2001; 4: 183-90.
65. Jagoe RT, Lecker SH, Gomes M, et al. Patterns of gene expression in atrophying skeletal muscles: response to food deprivation. FASEB J 2002; 16: 1697-712.
66. Lecker SH, Jagoe RT, Gilbert A, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004; 18: 39-51.
67. Gomes MD, Lecker SH, Jagoe RT, et al. Atrogin-1, a musclespecific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001; 98: 14440-5.
68. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Sci 2001; 294: 1704-8.
69. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996; 335: 1897-1905.
70. Liu JP, Baker J, Perkins AS, et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993; 75: 59-72.
71. Coleman ME, DeMayo F, Yin KC, et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 1995; 270: 12109-16.
72. Scicchitano BM, Rizzuto E, Musaro A. Counteracting muscle wasting in aging and neuromuscular diseases: The critical role of IGF-1. Aging (Albany NY) 2009; 1 451-7.
73. Musaro A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001; 27: 195-200.
74. Rosen CJ, Pollak M. Circulating IGF-I: New Perspectives for a New Century. Trends Endocrinol Metab 1999; 10: 136-41.
75. Rudman DM, Kutner MH, Rogers CM, et al. Impaired growth hormone secretion in the adult population: relation to age and adiposity. J Clin Invest 1981; 67: 1361-9.
76. Grounds MD. Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling. Biogerontology 2002; 3: 19-24.
77. Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nature Cell Biol 2001; 3: 1014-9.
78. Tran H, Brunet A, Griffith EC, Greenberg ME. The many forks in FOXO's road. Sci STKE. 2003; 2003(172): RE5.
79. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399-412.
80. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-68.
81. Murgia M, Serrano AL, Calabria E, et al. Ras is involved in nerveactivity- dependent regulation of muscle genes. Nat Cell Biol 2000; 2: 142-7.
82. Musaro A, McCullagh KJ, Naya FJ, et al. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nat 1999; 400: 581-5.
83. Sartori R, Schirwis E, Blaauw B, et al. BMP signaling controls muscle mass. Nat Genet 2013; 45: 1309-18.
84. Milan G, Romanello V, Pescatore F, et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nat Commun 2015; 6: 6670.
85. Thornberry NA, Lazebnik Y. Caspases: enemies within. Sci1998; 281: 1312-6.
86. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5: 897-907.
87. Enari M, Sakahira H, Yokoyama H, et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nat 1998; 391: 43-50.
88. Liu X, Zou H, Slaughter C, et al. A heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 1997; 89: 175-184.
89. Takahashi A, Alnemri ES, Lazebnik YA, et al. Cleavage of lamin A by Mch2 alpha but not CPP32: multiple interleukin 1 betaconverting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proc Natl Acad Sci USA 1996; 93: 8395-400.
90. Orth K, Chinnaiyan AM, Garg M, et al. The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol Chem 1996; 271: 16443-46.
91. Chen F, Chang R, Trivedi M, et al. Caspase proteolysis of desmin produces a dominant-negative inhibitor of intermediate filaments and promotes apoptosis. J Biol Chem 2003; 278: 6848-53.
92. Cryns V, Yuan J. Proteases to die for. Genes Dev 1998; 12: 1551-70.
93. Rheaume E, Cohen LY, Uhlmann F, et al. The large subunit of replication factor C is a substrate for caspase-3 in vitro and is cleaved by a caspase-3-like protease during Fas-mediated apoptosis. EMBO J 1997; 16: 6346-54.
94. Sandri M, El Meslemani AH, Sandri C, et al. Caspase 3 expression correlates with skeletal muscle apoptosis in Duchenne and facioscapulo human muscular dystrophy. A potential target for pharmacological treatment? J Neuropathol Exp Neurol 2001; 60: 302-12.
95. Brostrom MA, Brostrom CO. Calcium dynamics and endoplasmic reticular function in the regulation of protein synthesis: implications for cell growth and adaptability. Cell Cal 2003; 34: 345-63.
96. Hotokezaka Y, Van L K, Lo EH, et al. [alpha]NAC depletion as an initiator of ER stress-induced apoptosis in hypoxia. Cell Death Differ. 2009; 16: 1505-14.
97. Sawada N, Yao J, Hiramatsu N. et al. Involvement of hypoxiatriggered endoplasmic reticulum stress in outlet obstructioninduced apoptosis in the urinary bladder. Lab Invest 2008; 88: 553-63.
98. Tang C, Koulajian K, Schuiki I, et al. Glucose-induced beta cell dysfunction in vivo in rats: link between oxidative stress and endoplasmic reticulum stress. Diabetologia 2012; 55: 1366-79.
99. Rutkowski DT, Kaufman RJ. That which does not kill me makes me stronger: adapting to chronic ER stress. Trends Biochem Sci 2007; 32: 469-76.
100. Nakagawa T, Yuan J. Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis. J Cell Biol 2000; 150: 887-94.
101. Li C, Wei J, Li Y, et al. Transmembrane protein (TMEM214) mediates endoplasmic reticulum stress-induced caspase 4 enzyme activation and apoptosis. J Biol Chem 2013; 288: 17908-17.
102. Morishima N, Nakanishi K, Takenouchi H, et al. An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. J Biol Chem 2002; 277: 34287-94.
103. Yukioka F, Matsuzaki S, Kawamoto K, et al. Presenilin-1 mutation activates the signaling pathway of caspase-4 in endoplasmic reticulum stress-induced apoptosis. Neurochem Int 2008; 52: 683-7
104. Fujita E, Kouroku Y, Jimbo A, et al. Caspase-12 processing and fragment translocation into nuclei of tunicamycin-treated cells. Cell Death Differ 2002; 9: 1108-14.
105. Moorwood C, Barton ER. Caspase-12 ablation preserves muscle function in the mdx mouse. Hum Mol Genet 2014; 23: 5325-41.
106. Belizario JE, Lorite MJ, Tisdale MJ. Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. Br J Cancer 2001; 84: 1135-40.
107. Tisdale MJ. Biomedicine. Protein loss in cancer cachexia. Science 2000; 289: 2293-4.
108. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002; 2: 862-71.
109. Coletti D, Yang E, Marazzi G, et al. TNFalpha inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. EMBO J 2002; 21: 631-42.
110. Israel A. The IKK complex: an integrator of all signals that activate NF-kappaB? Trends Cell Biol 2000; 10: 129-33.
111. Relaix F, Weng X, Marazzi G, et al. Pw1, a novel zinc finger gene implicated in the myogenic and neuronal lineages. Dev Biol 1996; 177: 383-96.
112. Bonetto A, Aydogdu T, Kunzevitzky N, et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One 2011; 6: e22538.
113. Gilabert M, Calvo E, Airoldi A, et al. Pancreatic cancer-induced cachexia is Jak2-dependent in mice. J Cell Physiol 2014; 229: 1437-43.
114. Watchorn TM, Dowidar N, Dejong CH, et al. The cachectic mediator proteolysis inducing factor activates NF-kappaB and STAT3 in human Kupffer cells and monocytes. Int J Oncol 2005; 27: 1105-11.
115. Tisdale MJ. New cachexic factors. Curr Opin Clin Nutr Metab Care 1998; 1: 253-6.
116. Johns N, Stephens NA, Fearon KC. Muscle wasting in cancer. Int J Biochem Cell Biol 2013; 45: 2215-29.
117. Bonetto A, Aydogdu T, Jin X, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 2012; 303: E410-21.
118. Price F D, Von M J, Bentzinger C F, et al. Inhibition of JAK-STAT signaling stimulates adult satellite cell function. Nat Med 2014; 20: 1174-81.
119. Pelosi L, Berardinelli M G, De P L, et al. Functional and Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor Blockade. EBioMed 2015; 2: 285-93.
120. Tierney MT, Aydogdu T, Sala D, et al. STAT3 signaling controls satellite cell expansion and skeletal muscle repair. Nat Med 2014; 20: 1182-6.
121. Silva KA, Dong J, Dong Y, et al. Inhibition of Stat 3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J Biol Chem 2015; 290: 11177-87.
122. Du J, Wang X, Meireles C L. et al. Activation of caspase 3 is an initial step triggering muscle proteolysis in catabolic conditions. J Clin Invest 2004; 113: 115-23
123. Wang XH, Zhang L, Mitch WE, et al. Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity. J Biol Chem 2010; 285: 21249-57.
124. Wang XH, Mitch WE. Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol 2014; 10: 504-16.
125. Cecconi F, Levine B. The role of autophagy in mammalian development: cell makeover rather than cell death. Dev Cell 2008; 15: 344-57.
126. Sandri M. Autophagy in skeletal muscle. FEBS Lett 2010; 584: 1411-6.
127. Galluzzi L, Vicencio JM, Kepp O, et al. To die or not to die: that is the autophagic question. Curr Mol Med 2008; 8: 78-91
128. Dobrowolny G, Aucello M, Rizzuto E, et al. Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab 2008; 8: 425-36.
129. Aucello M, Dobrowolny G, Musaro A. Localized accumulation of oxidative stress causes muscle atrophy through activation of an autophagic pathway. Autoph 2009; 5: 527-9.
130. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42.
131. Mizushima N, Levine B, Cuervo AM, et al. Autophagy fights disease through cellular self-digestion. Nat 2008; 451: 1069-75.
132. Tanida I, Ueno T, Kominami E. Human light chain 3/MAP1LC3B is cleaved at its carboxyl terminal Met121 to expose Gly120 for lipidation and targeting to autophagosomal membranes. J Biol Chem 2004; 279: 47704-10.
133. Tanida I, Ueno T, Kominami E. LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol 2004; 36: 2503-18.
134. Deval C, Mordier S, Obled C, et al. Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting. Biochem J 2001; 360: 143-50.
135. Mammucari C, Schiaffino S, Sandri M. Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle. Autophagy 2008; 4: 524-6.
136. Mizushima N, Yamamoto A, Matsui M, et al. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 2004; 15: 1101-11.
137. Mammucari C, Milan G, Romanello V, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 2007; 6: 458-71.
138. McClung JM, Judge AR, Powers SK, et al. p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am J Physiol Cell Physiol 2010; 298: C542-9.
139. Klionsky DJ, Abdalla FC, Abeliovich H, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445-544.